Metformin as Added on Therapy in Patients With Ulcerative Colitis
This study tests whether adding the medication metformin to current ulcerative colitis treatments can help reduce symptoms like bloody diarrhea and inflammation. Ulcerative colitis is a chronic disease that affects the intestines, and this research explores if metformin might improve how well existing treatments work.
Key Objective: This trial is testing whether metformin can enhance the effectiveness of current ulcerative colitis medications and reduce disease symptoms.
Who to Consider: People with ulcerative colitis who are currently on standard treatments but are looking for additional ways to better control their symptoms should consider enrolling in this study.
Trial Parameters
Brief Summary
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilization
Eligibility Criteria
Inclusion Criteria: \- Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception Mild and moderate UC patients diagnosed and confirmed by the endoscope Exclusion Criteria: \- Breastfeeding Significant liver and kidney function abnormalities Diabetic patients Colorectal cancer patients Patients with severe UC Patients taking rectal or systemic steroids